The therapy is the first innovative monoclonal antibody developed by Shanghai Henlius Biotech,Inc. (stock code: 2696.HK) and
Over time, the partnership between the two companies is expected to expand further, continuing to leverage a product development team of experts and full commercial infrastructure within Syneos One to support Fosun Pharma USA’s growth.
“This partnership showcases our ability to provide fit-for-purpose solutions that encompass the entire product development continuum. Our ability to strategize and execute across multiple service lines, including medical affairs and commercial, makes us the premier partner for
Mousumi Sannigrahi, SVP, Head of Commercial, Innovative Medicine,
Specifically, for Serplulimab,
Syneos One solutions are unique in the market and can reduce program risk and optimize product development timelines, while maximizing return on investment. Specifically, Syneos One covers the full clinical development, medical affairs and commercialization continuum. These solutions provide small to mid-sized customers with an economic alternative to divesting, out-licensing, or co-promoting assets, and offers large biopharmaceutical customers further opportunity to reduce their fixed-cost infrastructure and can be an alternative approach to developing and promoting non-core and established assets.
About
We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics.
Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.
To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.
About Fosun Pharma USA Inc.
Fosun Pharma USA Inc., a subsidiary of Fosun Pharma, was founded in 2017 and continually works to enhance our existing portfolio of specialty pharmaceutical injectables and to build our pipeline with both innovative and generic pharmaceutical drugs. With strategic manufacturing partnerships around the world, Fosun Pharma USA Inc. delivers high-quality products that comply with international standards.
For more information, please visit our official website: https://fosunpharmausa.com/
About Fosun Pharma
Founded in 1994,
Fosun Pharma is patient-centered and clinical needs-oriented. The company enriches its innovative product pipeline through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma has formed technological platforms for innovative small molecule drugs, antibody drugs, and cell therapy with a focus on key disease areas including oncology and immunomodulation, metabolism and digestive system, and central nervous system. Fosun Pharma also vigorously explores cutting-edge technologies, such as RNA, oncolytic viruses, gene therapy and PROTAC, to enhance its innovation capabilities.
Guided by the 4IN strategy (Innovation, Internationalization, Integration, and Intelligentization), Fosun Pharma will uphold the development model of “innovation transformation, integrated operation, and steady growth", with the mission of creating shareholder values as well as promoting the global networks through strengthening its innovative R&D and in-licensing ability and enriching its product pipelines. Fosun Pharma will actively promote the digital and physical business layout in the pharmaceutical and healthcare industry and is committed to becoming a first-class enterprise in the global mainstream medical and health market.
For more information, please visit our official website: www.fosunpharma.com
Syneos Health Contacts: | |
Investor Relations | Press/Media |
Senior Vice President, Investor Relations | Executive Director, |
+1 919 745 2745 | +1 908 763 3428 |
Investor.Relations@syneoshealth.com | gary.gatyas@syneoshealth.com |
Fosun Pharma | |
Media Relations | |
Senior Manager, Public Relations and Global Communication | |
+1 917 698 5098 | |
Hanying.Wu@fosunpharmausa.com |
Source:
2023 GlobeNewswire, Inc., source